Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user plans to use a combination of tretinoin, topical minoxidil, and topical finasteride for hair loss treatment. They seek advice on application order, timing, and tretinoin dosage.

Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.

The user experienced significant hair thickening and temple hair growth after one year of using finasteride, minoxidil, and weekly dermarolling. They are considering asking their dermatologist about dutasteride.

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.

A user's 1-year progress using the God Stack, which is a combination of Dutasteride, Finasteride, oral minoxidil, RU58841, derma roller, ketoconazole shampoo, and stemoxydine. No side effects were experienced other than watery semen for the first few months.

Wait 12-24 hours after dermarolling before applying topical finasteride or minoxidil to minimize irritation and allow skin recovery. If irritation occurs, space treatments further apart.

The conversation is about a user seeking to buy Fluridil powder or join a group buy for it. They are looking for assistance in acquiring the product.

Transitioning from finasteride to dutasteride for hair loss, with suggestions to either slowly transition or frontload dutasteride. The user is also using minoxidil, nizoral, needling, and LLLT.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

The user experienced noticeable hair growth after 9 months using oral dutasteride, with full results expected in 20-24 months. They prefer oral treatments over topical minoxidil due to convenience.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

A 24-year-old male is increasing his dutasteride dosage from 0.5mg to 1mg daily due to continued hair thinning despite using finasteride, dutasteride, and topical minoxidil. Another user suggests trying oral minoxidil for potentially better results.

Dutasteride's half-life varies with dosage, and lower doses can be effective with fewer side effects compared to finasteride. Some users report different side effects with dutasteride and finasteride, and extreme dosages of dutasteride are unnecessary and potentially harmful.

A user's progress in treating their hair loss with Finasteride, Minoxidil and Dermarolling; they discussed details of their routine and others congratulated them on their success.

Diffuse thinners find shopping challenging due to harsh overhead lighting, but H&M's side lighting in fitting rooms is more flattering. Many users humorously suggest banning overhead lighting to improve the shopping experience.

Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.